VIEW MOREPotentially practice-changing results point to new standard-of -care treatments for patients with metastatic colorectal cancer
VIEW MOREEuropean Commission expands dostarlimab plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
VIEW MOREThe drug OMO-103, developed by Peptomyc, will be tested as a therapy for patients with advanced osteosarcoma
Latest News
25 January 2025
Potentially practice-changing results point to new standard-of -care treatments for patients with metastatic colorectal cancer
Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies...
23 January 2025
European Commission expands dostarlimab plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
The European Commission has approved dostarlimab in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary...
20 January 2025
VHIO participates in the European project AI4LUNGS: Advancing Lung Health with AI
Breathing is life, but for millions of people living with lung diseases, each breath can be a constant struggle. These...
16 January 2025
The drug OMO-103, developed by Peptomyc, will be tested as a therapy for patients with advanced osteosarcoma
This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology...
PRINCIPAL RESEARCHERS
Events
